DOI QR코드

DOI QR Code

Malignant Ascites after Subduroperitoneal Shunt in a Patient with Leptomeningeal Metastasis

  • Lee, Min-Ho (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jung-Il (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2011.05.17
  • Accepted : 2011.10.06
  • Published : 2011.10.28

Abstract

Leptomeningeal metastasis is a devastating complication of advanced stage cancer. It is frequently accompanied by hydrocephalus and intracranial hypertension that must be treated by ventriculoperitoneal shunts. However, there are actual risks of peritoneal seeding or accumulation of malignant ascites after the cerebrospinal fluid diversion procedure, though it has not been reported. Here, we present the case of a patient with non-small cell lung cancer with leptomeningeal metastasis in whom malignant ascites developed after a subduroperitoneal shunt.

Keywords

References

  1. Chamberlain MC : Leptomeningeal metastases : a review of evaluation and treatment. J Neurooncol 37 : 271-284, 1998 https://doi.org/10.1023/A:1005976926058
  2. Coelho Neto M, Ramina R, de Meneses MS, Arruda WO, Milano JB : Peritoneal dissemination from central neurocytoma : case report. Arq Neuropsiquiatr 61 : 1030-1034, 2003 https://doi.org/10.1590/S0004-282X2003000600028
  3. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E : Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol 108 : 248-250, 2008 https://doi.org/10.1016/j.ygyno.2007.09.024
  4. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. : A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 : 3394-3402, 1999
  5. Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, et al. : Leptomeningeal metastasis : survival and prognostic factors in 155 patients. J Neurol Sci 223 : 167-178, 2004 https://doi.org/10.1016/j.jns.2004.05.008
  6. Loiacono F, Morra A, Venturini S, Balestreri L : Abdominal metastases of medulloblastoma related to a ventriculoperitoneal shunt. AJR Am J Roentgenol 186 : 1548-1550, 2006 https://doi.org/10.2214/AJR.04.1718
  7. Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM : Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64 : 1625-1627, 2005 https://doi.org/10.1212/01.WNL.0000160396.69050.DC
  8. Reddy GK, Bollam P, Caldito G, Willis B, Guthikonda B, Nanda A : Ventriculoperitoneal shunt complications in hydrocephalus patients with intracranial tumors : an analysis of relevant risk factors. J Neurooncol 103 : 333-342, 2011 https://doi.org/10.1007/s11060-010-0393-4
  9. Rickert CH : Extraneural metastases of paediatric brain tumours. Acta Neuropathol 105 : 309-327, 2003
  10. Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH : Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 : 49-54; discussion 54-55, 2000
  11. Zada G, Chen TC : A novel method for administering intrathecal chemotherapy in patients with leptomeningeal metastases and shunted hydrocephalus : case report. Neurosurgery 67 : onsE306-onsE307; discussion onsE307, 2010

Cited by

  1. Surgical Treatment for Leptomeningeal Disease vol.24, pp.1, 2011, https://doi.org/10.1177/107327481702400107
  2. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions vol.33, pp.4, 2011, https://doi.org/10.1111/pcmr.12861